Liquid pharmaceutical composition

Abstract

The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.

Claims

1. A pharmaceutical liquid composition comprising sodium picosulfate, magnesium oxide, citric acid and malic acid.

2. The pharmaceutical liquid composition of claim 1, wherein from 50 mL to 500 mL of the composition provides a single effective dose.

3. The pharmaceutical liquid composition of claim 1, wherein from 150 mL to 200 mL of the composition provides a single effective dose.

4. The pharmaceutical liquid composition of claim 1, wherein the pharmaceutical liquid composition is aqueous.

5. The pharmaceutical liquid composition of claim 1, wherein pH of the pharmaceutical liquid composition ranges from 4.1 to 5.4.

6. The pharmaceutical liquid composition of claim 1, wherein the pharmaceutical liquid composition further comprises an excipient and purified water.

7. The pharmaceutical liquid composition of claim 6, wherein the excipient is at least one excipient selected from the group consisting of a pH adjuster, a stabilizer, a preservative, a sweetener and a fragrance ingredient.

8. The pharmaceutical liquid composition of claim 7, comprising a pH adjuster.

9. The pharmaceutical liquid composition of claim 8, wherein the pH adjuster is an alkalizing agent.

10. The pharmaceutical liquid composition of claim 9, wherein the alkalizing agent is at least one alkalizing agent selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium bicarbonate, ammonia solution, potassium citrate, triethanolamine and sodium citrate.

11. The pharmaceutical liquid composition of claim 1, wherein the sodium picosulfate, magnesium oxide, citric acid and malic acid have a weight ratio of 0.003 to 0.009:1 to 3:3.5 to 10.5:0.01 to 13 (sodium picosulfate:magnesium oxide:citric acid:malic acid).

12. The pharmaceutical liquid composition of claim 1, comprising about 0.005 parts by weight of sodium picosulfate, about 1.75 parts by weight of magnesium oxide, about 6 parts by weight of citric acid, about 4.19 parts by weight of malic acid, and about 75 parts by weight of water.

13. The pharmaceutical liquid composition of claim 1, wherein the composition has a pH in the range from about 4.1 to about 5.4, and wherein, when the composition is left for 24 months at room temperature, Substance A related to sodium picosulfate is generated in an amount of about 2.0 wt. % or less, and precipitation either does not occur or occurs at about 5.0 vol. % or less.

14. A method of treatment for cleansing the large intestine of a subject in need of such treatment, comprising administering to the subject an effective amount of the pharmaceutical liquid composition according to claim 1.

15. The method of claim 14, wherein the cleansing is performed to prepare the subject prior to surgery, colonoscopy or colon X-ray inspection.

16. A pharmaceutical composition comprising sodium picosulfate, magnesium oxide, citric acid and malic acid.

17. A method of preparing a pharmaceutical liquid composition comprising dissolving ingredients comprising sodium picosulfate, magnesium oxide, citric acid and malic acid.

18. The method of claim 17, comprising dissolving the pharmaceutical composition in water.

19. A pharmaceutical liquid composition prepared by the method of claim 17.

20. A pharmaceutical liquid composition prepared by the method of claim 18.

Description

DESCRIPTION OF DRAWINGS

(1) FIG. 1 is a process flow diagram illustrating a method of manufacturing a pharmaceutical liquid composition according to an embodiment of the present invention.

OTHER EMBODIMENTS

(2) Although the present invention may be variously changed and include several embodiments, particular embodiments shown in the drawings will be described in detail in a detailed description. However, it is to be understood that the present invention is not limited to the particular embodiments, and various changes, equivalences and substitutions may be made without departing from the scope and spirit of the invention.

EXAMPLES

Example 1

(3) A pharmaceutical liquid composition was prepared by dissolving, in purified water in a weight ratio of 75, sodium picosulfate:magnesium oxide:citric acid:dl-malic acid in a weight ratio of 0.005:1.75:6:4.19, sodium benzoate in a weight ratio of 0.043 as a preservative, disodium edetate hydrate in a weight ratio of 0.035 as a stabilizer, sodium hydroxide in a weight ratio of 2.1 as a pH adjuster, acesulfame potassium in a weight ratio of 0.1, and sucralose in a weight ratio of 0.1 as a sweetener, and a fragrance ingredient in orange flavor in a weight ratio of 0.043.

Comparative Example 1

(4) A powder composition was prepared by including sodium picosulfate:magnesium oxide:citric acid in a weight ratio of 0.005:1.75:6, sodium hydrogen carbonate in a weight ratio of 0.21 as an excipient, acesulfame potassium qs (quantum satis) as a sweetener, and a fragrance ingredient having orange flavor qs (quantum satis).

Example 2

(5) The contents of sodium picosulfate, magnesium oxide and citric acid that are main components of a solution obtained by dissolving the liquid composition of Example 1 in water of 150 mL were compared with those of a solution obtained by dissolving the powder composition of Comparative Example 1 in water of 150 mL. The content comparison method is an experiment method pursuant to British Pharmacopoeia 2004 Compound Sodium Picosulfate Powder for Oral Solution and the measurement was made by high performance liquid chromatography. The results are shown in Table 1 below.

(6) TABLE-US-00001 TABLE 1 Content Ingredient Name Criteria Example 1 Comparative Example 1 Sodium 90.0~110.0% 100.7% 100.1% picosulfate Magnesium oxide 90.0~110.0% 101.0% 101.4% Citric acid 90.0~110.0% 100.1% 99.7%

(7) As a result of the experiment, it can be seen from Table 1 that there is no substantial difference between the contents of the main components of Example 1 and Comparative Example 1. Therefore, both the powder composition and the liquid composition are considered to have the same effect as a colon cleanser.

Example 3

(8) A liquid composition was prepared by dissolving, in purified water in a weight ratio of 75, sodium picosulfate:magnesium oxide:citric acid in a weight ratio of 0.005:1.75:6, and adding, as a solubilizing agent, each of polyoxyethylene hydrogenated castor oil, polyethylene sorbitan monooleate, polyoxyethylene octyl dodecyl ether, polysorbate 20, polysorbate 60 and polysorbate 80 at 5.0 wt. % with respect to the total liquid weight. The liquid composition was left under the room temperature conditions (25° C., 60%) to check whether precipitation occurs, and a time point (day) when precipitation occurs at 5.0 vol. % on the bottom of a sample container was measured. The results are shown in Table 2 below.

(9) TABLE-US-00002 TABLE 2 Room Temperature Conditions Raw Material Name (when precipitation occurs: day) Polyoxyethylene hydrogenated castor 20 oil Polyethylene sorbitan monooleate 17 Polyoxyethylene octyl dodecyl ether 17 Polysorbate 20 23 Polysorbate 60 22 Polysorbate 80 20

(10) As can be seen in Table 2, it can be confirmed that precipitates are formed at 5.0 vol. % or more as a result of applying a solubilizing agent, and the solubilizing agent does not contribute to prevention of precipitation.

Example 4

(11) A liquid composition was prepared by dissolving, in purified water in a weight ratio of 75, sodium picosulfate:magnesium oxide:citric acid in a weight ratio of 0.005:1.75:6, using, as organic acid in a weight ratio of 4.19, each of citric acid, dl-malic acid, maleic acid, tartrate, fumaric acid, lactic acid, sodium citrate, aspartic acid, succinic acid, glutamic acid, hydrochloric acid, phosphoric acid, sulfuric acid and acetic acid, and adding, as a pH adjuster, sodium hydroxide in a weight ratio of 2.1 for each pH. The liquid composition was left for 24 months under the room temperature conditions (25° C., 60%) to check whether precipitation occurs. A time point (day) when precipitation occurs at 5.0 vol. % on the bottom of a sample container was measured and shown in Table 3 below. The content of the substance related to sodium picosulfate produced after 24 months was measured and shown in Table 4 below.

(12) TABLE-US-00003 TABLE 3 Room Temperature Conditions Raw Material Name pH (when precipitation occurs: day) Sodium hydroxide + 5.4 2 Citric acid 4.7 18 4.1 280 Sodium hydroxide + 5.4 — dl-malic acid 4.7 — 4.1 — Sodium hydroxide + 5.4 2 Maleic acid 4.7 10 4.1 350 Sodium hydroxide + 5.4 2 Tartrate 4.7 2 4.1 77 Sodium hydroxide + 5.4 2 Fumaric acid 4.7 18 4.1 98 Sodium hydroxide + 5.4 2 Lactic acid 4.7 14 4.1 105 Sodium hydroxide + 5.4 2 Sodium citrate 4.7 10 4.1 91 Sodium hydroxide + 5.4 2 Aspartic acid 4.7 18 4.1 77 Sodium hydroxide + 5.4 2 Succinic acid 4.7 18 4.1 98 Sodium hydroxide + 5.4 2 Glutamic acid 4.7 14 4.1 98

(13) As can be seen in Table 3, it can be confirmed that precipitation occurs within 24 months in all cases of organic acids other than malic acid.

(14) TABLE-US-00004 TABLE 4 Raw Material Name pH Room Temperature Conditions (wt. %) Sodium hydroxide + 5.4 0.19 Citric acid 4.7 0.32 4.1 2.61 Sodium hydroxide + 5.4 0.25 dl-malic acid 4.7 0.39 4.1 1.98 Sodium hydroxide + 5.4 0.31 Maleic acid 4.7 0.49 4.1 2.91 Sodium hydroxide + 5.4 0.26 Tartrate 4.7 0.46 4.1 2.97 Sodium hydroxide + 5.4 0.18 Fumaric acid 4.7 0.60 4.1 2.75 Sodium hydroxide + 5.4 0.26 Lactic acid 4.7 0.74 4.1 2.74 Sodium hydroxide + 5.4 0.18 Sodium citrate 4.7 0.46 4.1 2.25 Sodium hydroxide + 5.4 0.21 Aspartic acid 4.7 0.58 4.1 2.95 Sodium hydroxide + 5.4 0.24 Succinic acid 4.7 0.66 4.1 2.18 Sodium hydroxide + 5.4 0.15 Glutamic acid 4.7 0.49 4.1 2.27

(15) As can be seen in Table 4, it was confirmed that in the case of including malic acid, Substance A related to sodium picosulfate (4-[(pyridine-2-yl)(4-hydroxyphenyl)methyl]phenyl sodium sulfate) is generated at 2.0 wt. % or less in the above-mentioned pH range.

(16) Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings.

(17) FIG. 1 is a process flow diagram illustrating a method of preparing a pharmaceutical liquid composition according to an embodiment of the present invention.

(18) The method of preparing a pharmaceutical liquid composition may include the steps of weighing citric acid and magnesium oxide to prepare a mixture (S110), mixing malic acid and sodium hydroxide with the mixture prepared in step S110 (S120), mixing sodium picosulfate with the mixture prepared in step S120 (S130), and adding purified water to the mixture in step S130 (S140).

(19) In step S110, a pH adjuster, a stabilizer, a sweetener and the like may be added to the mixture.

(20) In some cases, step S110 and step S120 may be performed at the same time, and steps S110, S120 and S130 may be performed at the same time. Further, although steps S110, S120 and S130 have been illustrated in the order mentioned, the order is not limited thereto.

(21) Although the embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.